EIF4A1 and acute myeloid leukemia: Therefore, additional studies in human patient samples are required to reveal whether eIF4Ai can be applied as a strategy to target mTORC1-dependent AML growth across the diverse genotypes that characterize human diseases and/or define biomarkers predictive of response.